Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells

Oleksandr H Minchenko, Katsuya Tsuchihara, Dmytro O Minchenko, Andreas Bikfalvi, Hiroyasu Esumi

Oleksandr H Minchenko, Dmytro O Minchenko, Department of Molecular Biology, Palladin Institute of Biochemistry, Kiev 01601, Ukraine
Katsuya Tsuchihara, Hiroyasu Esumi, Department of Innovative Oncology, National Cancer Center, Kashiwa, Chiba 277-8577, Japan
Dmytro O Minchenko, Department of Pediatrics, Bogomolets National Medical University, Kiev 01601, Ukraine
Andreas Bikfalvi, INSERM U1029 Molecular Angiogenesis and Cancer Microenvironment Laboratory, University Bordeaux I, 33405 Talence, France

Author contributions: Minchenko DO and Minchenko OH contributed equally to this work; Minchenko OH and Esumi H contributed to conception and design; Minchenko OH and Minchenko DO wrote the paper; Esumi H, Tsuchihara K, Minchenko OH and Bikfalvi A revised the article critically for important intellectual content and final approval of the version to be published.

Correspondence to: Oleksandr H Minchenko, PhD, Professor, Head, Department of Molecular Biology, Palladin Institute of Biochemistry, 9 Leontovicha St., Kiev 01601, Ukraine.ominchenko@yahoo.com
Telephone: +38-44-2356151 Fax: +38-44-2796365
Received: February 22, 2014 Revised: March 22, 2014
Accepted: May 19, 2014
Published online: October 14, 2014

Abstract

Enzymes 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 and -4 (PFKFB-3 and PFKFB-4) play a significant role in the regulation of glycolysis in cancer cells as well as its proliferation and survival. The expression of these mRNAs is increased in malignant tumors and strongly induced in different cancer cell lines by hypoxia inducible factor (HIF) through active HIF binding sites in promoter region of PFKFB-4 and PFKFB-3 genes. Moreover, the expression and hypoxia responsibility of PFKFB-4 and PFKFB-3 was also shown for pancreatic (Panc1, PSN-1, and MIA PaCa-2) as well as gastric (MKN45 and NUGC3) cancer cells. At the same time, their basal expression level and hypoxia responsiveness vary in the different cells studied: the highest level of PFKFB-4 protein expression was found in NUGC3 gastric cancer cell line and lowest in Panc1 cells, with a stronger response to hypoxia in the pancreatic cancer cell line. Overexpression of different PFKFB in pancreatic and gastric cancer cells under hypoxic condition is correlated with enhanced expression of vascular endothelial growth factor (VEGF) and Glut1 mRNA as well as with increased level of HIF-1α protein. Increased expression of different PFKFB genes was also demonstrated in gastric, lung, breast, and colon cancers as compared to corresponding non-malignant tissue counterparts from the same patients, being more robust in the breast and lung tumors. Moreover, induction of PFKFB-4 mRNA expression in the breast and lung cancers is stronger than PFKFB-3 mRNA. The levels of both PFKFB-4 and PFKFB-3 proteins in non-malignant gastric and colon tissues were more pronounced than in the non-malignant breast and lung tissues. It is interesting to note that Panc1 and PSN-1 cells transfected with dominant/negative PFKFB-3 (dnPFKFB-3) showed a lower level of endogenous PFKFB-3, PFKFB-4, and VEGF mRNA expressions as well as a decreased proliferation rate of these cells. Moreover, a similar effect had dnPFKFB-4. In conclusion, there is strong evidence that PFKFB-4 and PFKFB-3 isoenzymes are induced under hypoxia in pancreatic and other cancer cell lines, are overexpressed in gastric, colon, lung, and breast malignant tumors and undergo changes in their metabolism that contribute to the proliferation and survival of cancer cells. Thus, targeting these PFKFB may therefore present new therapeutic opportunities.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3; 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4; Hypoxia; Hypoxia inducible factor; Panc1; PST-1; MKN45; NUGC3; Gastric cancer;
INTRODUCTION

Pancreatic adenocarcinoma is an aggressive disease with a high mortality rate. Despite intensive efforts, pancreatic cancer remains a formidable challenge for oncologists[1]. Investigation of the molecular and genetic bases of pancreatic as well as other cancers is very important for understanding tumor formation and growth as well as for development of anticancer strategies. Hypoxia has been recognized as one of the fundamentally important features of solid tumors and plays a critical role in various cellular and physiologic events, including cell proliferation, survival, angiogenesis, metabolism, as well as tumor growth, invasion and metastasis[1-5]. Moreover, hypoxia has the multifaceted role in the hallmarks of human cancer, including pancreatic cancer. Hypoxia-inducible factor 1 (HIF-1), represent key features in cell biochemistry, physiology and molecular biology.

Tumors are usually exposed to a hypoxic microenvironment due to their irregular growth and insufficient blood supply while pancreatic tumors have enhanced vascular supply[5,30]. Moreover, there is heterogeneity and genomic complexity between pancreatic tumors as well as hierarchy of cancer cells with different properties, including a subpopulation of cancer stem cells that are inherently resistant to traditional therapies[8]. Activation of genes that ameliorate or compensate for the oxygen deficit, especially of mRNAs involved in glycolysis and facilitate proliferation is important in adaptations to hypoxia[9]. A high rate of glycolytic flux, even in the presence of oxygen, is a central metabolic hallmark of neoplastic tumors. The high glucose metabolism of cancer cells is caused by a combination of hypoxia inducible transcription factors, activation of oncogenic proteins and the loss of tumor suppressor function. Over-expression of HIF-1α or HIF-2α and MYC, activation of RAS and loss of TP53 and/or other tumor suppressor functions each have been found to stimulate glycolysis in part by activating a family of regulatory bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFB) and hexokinases[16-18].

PFKFB AS AN IMPORTANT FACTOR OF TUMOR GROWTH

Enzyme PFKFB controls of glycolysis through maintaining the cellular levels of fructose-2,6-bisphosphate, which is considered to be the major allosteric activator of 6-phosphofructo-1-kinase, a rate-limiting enzyme of glycolysis[19,20]. Thus, the PFKFB enzymes control glycolysis through fructose-2,6-bisphosphate level[20-23]. There are 4 different genes encode variable isoforms of this enzyme. Importantly, most cells and tissues express more than one isoform[23,24]. PFKFB enzyme also plays an important role in the Warburg effect and cancer growth[25,17,18].

Overexpression of PFKFB-3 as well as other variants of PFKFB is observed in various human cancers[20-33]. Moreover, enhanced expression of PFKFB as well as hexokinase 2 is an obligatory factor of activated tumor cell glycolysis and increased its proliferation[15,24,32,33].

The expression of different PFKFBs (PFKFB-1, PFKFB-2, PFKFB-3 and PFKFB-4) is induced by hypoxia in vitro in organ-specific manner[24]. At the same time, in vivo experiments clearly demonstrated that hypoxia affects the expression only two variants of PFKFB (3 and 4) mRNA in different cell lines[20,29,31-33]. In promoter region of PFKFB-4 and PFKFB-3 genes was identified HIF responsive element which bind transcription factor HIF and mediate hypoxic regulation, because deletion or point mutation of this HIF responsive element eliminates the hypoxic regulation both in vitro and in vivo[26,29,31-33]. Moreover, the phosphorylation - dephosphorylation of PFKFB isoenzymes is important for enhancing of glycolysis by hypoxia as well as by fructose-2,6-bisphosphate in monocytes upon activation[19,38,39]. There is also data supporting an important role for PFKFB-3 protein phosphorylation in the increased glycolysis, angiogenesis and tumor progression[40]. Thus, highly phosphorylated variant of PFKFB-3 was found in cancer cells as well as in other cells, including vascular endothelial cells[41].

Recently, a novel mechanism by which MK2, MAPK (mitogen-activated protein kinase)-activated protein kinase 2, a key component of the MAPK pathway, up-regulates glycolysis in response to stress in cancer cells was described[42]. By phosphorylating specific PFKFB3 residues, MK2 promotes both increased its gene transcription and allosteric activation.

It was also shown a significant increase of PFKFB-3 in the nuclei, which associates with enhanced cell prolif-
eration through cyclin-dependent protein kinase[44]. Moreover, PFKFB-3 isoenzyme is degraded by the E3 ubiquitin ligase APC/C-CDH1, which also degrades cell-cycle proteins[42]. Thus, this ubiquitin ligase is linking glycolysis to cell proliferation mainly through PFKFB-3 enzyme, which promote glycolysis. It was shown that both aerobic glycolysis and proliferation are prevented by overexpression of this ubiquitin ligase and enhanced by its silencing. Furthermore, activation of glycolysis, as essential factor of cell proliferation, in the presence of active ubiquitin ligase APC/C-CDH1 does not change the rate of cell proliferation[42]. Recently was also shown that PTEN (phosphatase and tensin homolog) enhances interaction between PFKFB3 and E3 ligase APC/C-CDH1, and overexpression of CDH1 down-regulates the PFKFB3 protein level in wild-type, but not in PTEN-deficient cells[40]. Moreover, PTEN knockout cells were found to have high protein levels of PFKFB3 that has important consequences for cell proliferation.

There is data that ubiquitin ligase SKP1-CUL1-F(SCF)-beta-TrCP also participate in glycolysis regulation during the cell cycle through PFKFB3 because this enzyme or activation the glycolytic enzyme 6-phosphofructo-1-kinase is needed for glycolysis up-regulation[44]. Besides that, the induction of de novo lipid synthesis from glucose in prostate adenocarcinoma cells by androgen requires transcriptional up-regulation of PFKFB-2 and phosphorylation of PFKFB-2 generated by the PI3K/AKT signal pathway to supply the source for lipogenesis[45]. The increased glycolytic flux through the enhanced expression of PFKFB3 gene was also observed after interaction of adenovirus with macrophage TLR4 receptor agonists[46]. Thus, the enzymes of PFKFB family participate in the regulation of glucose metabolism through glycolysis as well as in the control of the cell cycle, apoptosis, tumor growth, and invasiveness.

It is interesting to note that the transcriptional corepressor myeloid translocation gene 16 (MTG16) is found in multiple transcription factor-containing complexes as a regulator of gene expression implicated in development and tumorigenesis. MTG16 can serve as a brake on glycolysis, a stimulator of mitochondrial respiration and an inhibitor of cell proliferation through suppression of PFKFB-3, PFKFB-4 and pyruvate dehydrogenase kinase isozyme 1 (PDK1)[47]. Furthermore, hypoxia-stimulated production of PFKFB3, PFKFB4 and PDK1 was inhibited by MTG16 expression.

Several alternative splice variants for PFKFB-3 were identified in normal and cancer cells which possibly are important for malignant tumor growth[30,32,33]. All these splice variants have similar N-terminus and catalytic both 6-phosphofructo-2-kinase and fructose-2,6-bisphosphatase domains, but differ in C-terminal regulatory region. It is possible that a variable C-terminus provide not only for differ regulatory properties and for a variable surviving of PFKFB-3 splice variants. Moreover, the expression of PFKFB-3 alternative splice variants in vivo differs in various organs and spectrum of these splice variants changes in rat model of diabetes in organ-specific manner[51].

Recent data[52-54] showed that PFKFB-4, which expression at mRNA and protein levels is strongly induced in the lung and breast cancers, has also pleiotropic functions. This variant of PFKFB together with other members of PFKFB family participates in the regulation of glycolysis and also promotes tumor growth and survival of cancer cells[30,33,32,56]. It was shown that PFKFB4 is required to balance glycolytic activity and antioxidant production to maintain cellular redox balance in prostate cancer cells[52]. Moreover, depletion of PFKFB4 inhibited tumor growth in a xenograft model, indicating that it is required under physiologic nutrient levels[52]. PFKFB4 mRNA expression was also found to be greater in metastatic prostate cancer compared with primary tumors[52]. Moreover, induction of apoptosis by sulforaphane in human hepatic cancer cells mediated by hypoxia inducible factor-1-dependent pathway through inhibition of PFKFB4[53]. Thus, PFKFB4, a glycolytic enzyme that shunts glucose into the pentose phosphate pathway for NADPH production, as a critical node for the survival of cancer cells[52-54,56].

Aerobic glycolysis links the high rate of glucose fermentation to cancer[37]. It was found that the regulatory glycolytic enzyme PFKFB4 is essential for prostate cancer cell survival by maintaining the balance between the use of glucose for energy generation and the synthesis of antioxidants. Cancer cells undergo several changes in their metabolism that contribute to the proliferation and survival of cancer cells. Blocking PFKFB4 induces reactive oxygen species and cancer cell death. Thus, targeting PFKFB4 may therefore present new therapeutic opportunities.

It is interesting to note that non-malignant gastric and colon tissues in contrast to lung and breast tissues have higher level of PFKFB-4 protein; at the same time, no significant differences in mRNA levels[30,32,33]. It is possible that there is some specific mechanism of PFKFB-4 protein stabilization as well as some additional functions of this enzyme in non-malignant gastric and colon tissues. These aspects of PFKFB biochemistry warrants further investigation.

Several alternative splice variants were identified for human, mouse and rat PFKFB-4[58-60]. Alternative splice variant with modified N-terminus was identified for PFKFB-4 in melanoma DB-1 cells[58]. Its expression was very high in these cells and is possibly related to melanoma growth. Other alternative splice variants of PFKFB-4 mRNA with modified C-terminus were found in rat tissues[59]. One of them with a modified C-terminal part was observed only in the liver of rats treated by methyl tertial butyl ether, ecologically dangerous chemical compound[59]. It was not present in normal rat liver and lungs. Second alternative splice variant with deletion in fructose-2,6-bisphosphatase region is expressed in normal liver and lung tissues and its expression is affected by methyl tertial butyl ether[59]. Results of this investigation demonstrate the sensitivity of PFKFB-4 alternative splicing to the action of toxic chemical compounds, in particular methyl tertbutyl ether. Several unique alterna-
tive splice variants were identified in mouse brain and other tissues\[^{[60]}\]. One of them has two ORFs (for 6-phosphofructo-2-kinase and fructose-2,6-bisphosphatase) as a result of insert after the 7\(^{th}\) exon. Other alternative splice variants have inserts in kinase domain or a deletion in bisphosphatase domain\[^{[60]}\]. Its functional significance is not elucidated as of yet.

At the same time, the analysis of PFKFB-3 and PFKFB-4 expression as well as its regulation by hypoxia in pancreatic and gastric cancer cells, which significantly differ from many other malignant cells, is needed for further advance our knowledge on the mechanisms of different tumors progression. Recently, it was shown that excess glucose induces hypoxia-inducible factor-1\(^{\text{a}}\) in pancreatic cancer cells and stimulates glucose metabolism possibly through PFKFB as well as the migration of these cancer cells and that hypoxia strongly up-regulates the expression of PFKFB-4 and PFKFB-3\[^{[32,61]}\].

**PFKFB-4 AND PFKFB-3 GENE EXPRESSIONS IN PANCREATIC AND GASTRIC CANCER CELL LINES AND MOLECULAR MECHANISMS OF ITS REGULATION**

It was shown that different PFKFB genes are expressed in human pancreatic and gastric cancer cells and are up-regulated in hypoxic condition\[^{[32]}\]. Hypoxia induces the expression of these genes through transcription factor HIF binding sites to hypoxia responsible element (HRE) of PFKFB-4 and PFKFB-3 genes, because deletion or point mutation in these HRE eliminates hypoxic regulation of PFKFB-4 and PFKFB-3 genes\[^{[25,31,36,57]}\]. As shown in Figure 1, the expression of PFKFB-4 mRNA is detectable at very low level in both MKN45 and NUGC3 gastric cancer cell lines growing under normal condition. The expression of PFKFB-3 mRNA in these cell lines was significantly higher as compared to the PFKFB-4 mRNA\[^{[32]}\].

Exposure of MKN45 and NUGC3 gastric adenocarcinoma cells to hypoxia or dimethylxalylglycine, which suppress prolyl hydroxylase enzymes, significantly enhanced the expression of PFKFB4 as well as PFKFB3 genes ($P < 0.001$; Figures 1 and 2). At the same time, the expression of PFKFB-3 mRNA in Panc1 pancreatic cancer cell line ($P < 0.01$) growing under normal condition was lower as compared to gastric cancer cell lines, but for PFKFB-4-slightly higher\[^{[32]}\]. Moreover, the basal level of PFKFB-4 mRNA expression as well as its hypoxia responsiveness was more robust as compared to PFKFB-3 mRNA\[^{[32]}\]. Thus, there is a difference in the basal level of these two variants of PFKFB mRNA between gastric and pancreatic cancer cells as well as in its sensitivity to hypoxia and dimethylxalylglycine.

At the same time, the protein level of PFKFB-4 isoenzyme in non-treated gastric adenocarcinoma cells was much higher as compared to pancreatic cancer cells (Figure 3). Moreover, the protein level of PFKFB-4 in NUGC3 gastric cancer cells is significantly higher than in MKN45 cells. Hypoxia and dimethylxalylglycine strongly enhances the expression of PFKFB-4 at protein level in pancreatic and gastric cancer cell lines. This increase of PFKFB-4 protein expression varies in different cancer cell lines possibly because these gastric and pancreatic cells have significantly different constitutive level of PFKFB-4 protein. Moreover, no strong correlation is present between mRNA and protein of PFKFB-4 in the pancreatic and gastric malignant cells in normoxic as well as in hypoxic condition\[^{[32]}\]. This data agrees with results of previous investigations\[^{[31]}\].

It is interesting to note that the level of PFKFB-4 mRNA and protein differs in different mammary gland adenocarcinoma cell lines both in normal condition and after hypoxic exposure\[^{[31]}\]. Thus, the level of PFKFB-4 mRNA is more pronounced in the T47D malignant cell line as compared to MCF7 cells both in normal condition and after hypoxia. At the same time, the protein level of PFKFB-4 is much higher in the MCF7 cells of T47D cell line in normal condition as well as after hypoxic exposure. Other cell lines (SKBR3 and MDA-MB-468) have similar level of PFKFB-4 mRNA expression both in normal condition and upon hypoxia. Unexpectedly, in MDA-MB-468 mammary gland adenocarcinoma cells PFKFB4 protein was detected at negligible level at the same ex-

---

**Figure 1** Effect of hypoxia (H) and hypoxia mimic dimethylxalylglycine (I) on the expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 and -4 mRNA in human gastric cancer cell lines MKN45 and NUGC3 and pancreatic cancer cell line Panc1. Measured by ribonuclease protection assay. N: Control (normoxic) cells\[^{[32]}\]. PFKFB: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.
perimental conditions, which were used for SKBR3 and other mammary gland adenocarcinoma cell lines\[31]. In contrast, the level of PFKFB-4 mRNA is correlated with corresponding protein level both in SKBR3 and BT549 cell lines.

Really, the protein level of PFKFB-4, which in Panc1 pancreatic cancer cells is much lower as compared to gastric cancer cells and correlates with stronger induction of both PFKFB-4 mRNA and protein expressions upon hypoxia. At the same time, the hypoxia-induced PFKFB-4 protein level in Panc1 cells is in fact lower when compared to the level of this protein in NUGC3 cells. Moreover, the high PFKFB-4 protein level in NUGC3 gastric cancer cells is correlated with the lower induction of PFKFB-4 mRNA and protein expressions upon hypoxia; on the other hand, the level of PFKFB-4 protein in hypoxia-treated cells is very high as compared to the levels of PFKFB-4 protein in both Panc1 and MKN45 control or hypoxia-treated cells\[32]. This difference between mRNA and protein levels of PFKFB-4 which in the different pancreatic and gastric cancer cells is possibly related to the mechanisms controlling PFKFB4 protein stability. However, the precise molecular mechanism for these discrepancies is complex and possibly includes PFKFB-4 enzyme posttranslational modification or its stability in a cell-specific manner and warrants further detailed investigation.

The induction of PFKFB-3 mRNA expression in the NUGC3 gastric cancer cell line by hypoxia and dimethyloxalylglycine is more pronounced as compared to PFKFB-4 mRNA expression. It is important to note that the expression PFKFB-3 mRNA in the Panc1 pancreatic cancer cells has the lowest hypoxia responsiveness as compared to both gastric cancer cell lines. We have previously shown that the hypoxic induction of PFKFB-3 mRNA expression in mammary gland cancer cells is more robust in MCF7 and T47D breast cancer cells (estrogen receptor-positive cell lines) as compared to SKBR-3 and MDA-MB-468 cells (estrogen receptor-negative cell lines)\[31]. The dissimilar sensitivity of the PFKFB-3 gene expression to induction by hypoxia was also shown for other cell lines, like HeLa, Hep3B, RPE, and fibroblasts, while induction of Glut1 mRNA by hypoxia was similar in all these cell lines\[31].

It is interesting to note that the induction of PFKFB-4 mRNA expression by hypoxia was simulated by dimethyloxalylglycine in different pancreatic and gastric as well as in many other cancer cell lines\[25,27,31,32]. Dimethyloxalylglycine, a specific inhibitor of prolyl hydroxylases, is an oxoglutarate analog, which protects the HIF-1α protein from proteasomal degradation and significantly increases its level\[59]. Suppression of prolyl hydroxylase enzymes can induce the level and functional activity of HIF-1α under normoxia and mimics hypoxic condition\[62]. Induction of PFKFB-4 mRNA synthesis by hypoxia is mediated by the hypoxia responsive element located in the promoter region of this gene which is similar to the same elements, described in different hypoxia responsive genes, including PFKFB-3 gene\[25,59,60].

As shown in Figure 4A, hypoxia increases the expression level of PFKFB-3 and PFKFB-4 as well as VEGF and Glut1 genes in both gastric and pancreatic cancer
The expression of HIF-1α mRNA is significantly decreased both under hypoxia and dimethylglyoxaline glyoxal synthesis. It is possible that this discrepancy between HIF-1α mRNA and protein levels, which was found in different gastric, pancreatic and many other cancer cell lines, is related to the divergence in mechanisms which control the stability of HIF-1α mRNA and protein. Thus, the hypoxic induction of HIF-1α protein expression is a result of its stabilization, possibly mediated by specific prolyl hydroxylase enzymes, oxygen- and iron-dependent, which utilize oxoglutarate as a co-substrate. At the same time, the decreased expression of HIF-1α mRNA both under hypoxia and dimethylglyoxaline glyoxal synthesis is possibly mediated by suppression of transcription or by its increased degradation.

The expression mRNA level of PFKFB variant 3 and 4 was also investigated in two other pancreatic cancer cell lines: PSN-1 and MIA PaCa-2 (Figures 5 and 6). Hypoxia strongly induces (P < 0.001) the expression of both PFKFB4 and PFKFB3 genes in PSN-1 and MIA PaCa-2 cancer cells being more robust for PFKFB4 gene. Moreover, hypoxic induction of PFKFB4 and PFKFB3 gene expressions in both these pancreatic cancer cell lines cor-
October 14, 2014 | Volume 20 | Issue 38

Minchenko OH et al. PFKFB expression in pancreatic cancer

Figure 7 Representative polyacrylamide gel autoradiograph employed in a typical ribonuclease protection assay of different 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase genes (PFKFB-1, PFKFB-2, PFKFB-3, and PFKFB-4), GLUT1, hypoxia inducible factor-1α, and different alternative splice variants of VEGF-A in gastric malignant tumors (T) and non-malignant tissue counterparts (N) from same patients. The 18S RNA expressions were used as control of RNA quantity used for analysis[32]. HIF: Hypoxia inducible factor; PFKFB: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.

relates with a strong increase of GLUT1 gene expression ($P < 0.001$).

In conclusion, this chapter provides evidence that PFKFB-4 and PFKFB-3 mRNA are expressed in different cancer cell lines, including pancreatic and gastric adenocarcinoma cells, and strongly respond to hypoxia possibly through a HIF- dependent mechanism using active HIF-binding sites in PFKFB4 and PFKFB3 genes. At the same time, no clear correlation is existent between different variants of PFKFB mRNA expressions and its protein levels in different cancer cell lines both in normoxic and hypoxic conditions. Moreover, hypoxic induction of HIF-1α protein level correlates with a reduction of HIF-1α mRNA expression in these cell lines. Thus, there is an opposite correlation between hypoxic regulation of PFKFB-4 mRNA and protein levels in different hypoxia-treated adenocarcinoma cells in vitro[31,32,36,37]. It is possible that permanent degradation of HIF-1α protein in normoxic condition support high level expression of corresponding mRNA needed for synthesis of this protein. At the same time, stabilization of HIF-1α protein under hypoxia suppresses transcription of this gene or/ and initiates the degradation of HIF-1α mRNA.

EXPRESSION OF DIFFERENT PFKFB IN HUMAN GASTRIC, COLON, LUNG, AND BREAST MALIGNANT TUMORS

There is data that PFKFB-4 and PFKFB-3 mRNA and protein expressions are significantly increased ($P < 0.001$) in gastric cancers as compared to corresponding non-malignant tissue counterparts from the same patients (Figures 7 and 8)[30,33]. This increase in the expression of these PFKFB genes in gastric malignant tumors correlates with the up-regulation of HIF-1α and known HIF-dependent genes GLUT1 and VEGF ($P < 0.001$). Moreover, the expression of PFKFB-1 and PFKFB-2 mRNA is also increased in gastric cancer tissue. It is interesting to note that the expression level of different PFKFB mRNAs in non-malignant stomach tissue was highest for PFKFB-2, much less for PFKFB-3 and slight for PFKFB-4 and PFKFB-1[32].

As shown in Figure 9, PFKFB-4 and PFKFB-3 mRNA are also overexpressed ($P < 0.001$) in lung, colon, and breast cancers as compared to corresponding non-malignant tissue counterparts from the same patients being more pronounced for PFKFB-4 in lung and breast tumors[30,32,69]. Up-regulation of PFKFB-2 mRNA is also shown for lung cancers[70]. Moreover, the level of GLUT1 and VEGF mRNA expressions is also significantly increased ($P < 0.001$) in all these cancer tissues, especially GLUT1 in lung and colon tumors (Figure 10)[30,34]. Western analysis of PFKFB-4 and PFKFB-3 proteins as well as HIF-1α protein clearly demonstrated its up-regulation in all analysed tumors with more pronounced changes in PFKFB-4 protein in lung and breast cancers (Figure 11)[30,32,33]. Thus, overexpression of PFKFB-3, PFKFB-4 and PFKFB-2 is observed in various human cancers through various mechanisms: by a combination of hypoxia inducible transcription factors (for PFKFB-4 and PFKFB-3), activation of oncogenic proteins and the loss of tumor suppressor function[32,33,71].

Recently, it was shown that amino acid activates AKT-dependent PFKFB2 phosphorylation at Ser-483 and that this activation was mediated by the PI3K and p38 signaling pathways[71]. Furthermore, AKT inactivation blocked PFKFB2 phosphorylation and fructose-2,6-bisphosphatase production, thereby suggesting that the above signaling pathways converge at AKT kinase. Moreover, MACC1 (MUC1, mucin 1, cell surface associated) may affect tumor metabolism partly through expression and phosphorylation of PFKFB2[72].

At the same time, the protein level of both PFKFB-4 and PFKFB-3 is significantly different in non-malignant lung, breast, colon, and gastric tissues being more pronounced for colon and gastric tissues. It is interesting to note that the level of PFKFB-4 protein in all studied cancers (lung, breast, colon, and gastric) was also higher as compared to the PFKFB-3 isozyme (Figure 11). Thus, the main protein isoform of PFKFB enzyme family expressed in lung, breast, colon, and gastric malignant tumors is PFKFB-4.

Moreover, there is data that hypoxia is needed for tumor progression and initiates the endoplasmic reticulum stress for induction of neovascularization and apoptosis inhibition[73-76]. It is known that some PFKFB enzymes are components of the endoplasmic reticulum stress and participate in proliferation processes[77]. Recently, it was shown that PFKFB-3-driven glycolysis participates in vessel sprouting process which strongly depends upon endoplasmic reticulum stress[77,78,79]. Thus, endothelial cells relied on glycolysis rather than on oxidative phosphorylation for ATP production and loss of the glycolytic activator PFKFB3 in endothelial cells impaired.
Moreover, the glycolytic activator PFKFB3 regulates stalk cell proliferation and renders endothelial cells more competitive to reach the tip. The induction of different PFKFB as well as tumor angiogenesis and growth is realized not only through activation of transcription factor HIF\(^{7,14,34,73,82-86}\). For PFKFB3 it was shown that its transcription as well as allosteric activation is promoted by MAPK pathway\(^{87}\).

Many growth factors may contribute to cancer progression, including pancreatic cancer, through induction of the expression of genes without hypoxia responsive elements\(^{88}\). Moreover, hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation and growth\(^{89}\). Recently, it was shown that clathrin heavy chain promotes growth and angiogenesis of pancreatic adenocarcinoma, which is an aggressive disease with a high mortality rate, through the regulation of HIF-1\(\alpha\) and VEGF signaling and that hypoxia-induced pancreatic cancer cells invasion is also mediated by transcription factor HIF\(^{85,90}\). One of the key functions of clathrin heavy chain protein is to bind with the HIF-1\(\alpha\) protein, increasing the stability of this protein and facilitating its nuclear translocation, thereby regulating the expression of VEGF. Thus, suppression of clathrin heavy chain either by shRNA or by specific antibody inhibited pancreatic adenocarcinoma growth and angiogenesis\(^{85}\).

A better understanding of the impact of PFKFB gene networks regulation on glycolysis as well as cell cycle control, apoptosis and cell survival promises to shed light on the emerging association between PFKFB-3, PFKFB-4,
cell proliferation and cancer. These provide rationale for the development of agents that selectively inhibit the PFKFB3 and PFKFB-4 enzymes as antineoplastic agents. Recently was shown that inhibition of PFKFB-3 activity suppresses glycolytic flux and tumor growth by rapid induction of apoptosis in transformed cells \[91,92\]. It is possible, that the stimulation of glycolysis in cancer cells results by multimodal mechanism of stress stimuli affecting PFKFB3 transcriptional regulation and kinase activation by protein phosphorylation \[41\]. Moreover, the glycolytic enzyme PFKFB3 regulates autophagy and inhibition of PFKFB3 in tumor cells would induce autophagy as a pro-survival mechanism and inhibitors of autophagy could increase the anti-tumor effects of PFKFB3 inhibitors \[93,94\].

Previously, we have shown that suppression of PFKFB-3 and PFKFB-4 expression \(P < 0.05-0.01\) in pancreatic Panc1 and PSN-1 cancer cells by dominant/negative technology also decreases VEGF expression \(P < 0.05\) and proliferation rate \(P < 0.05\) of these cells (Figures 12-14) \[95\]. For this aim we introduced point mutation in ATP-binding domain of 6-phosphofructo-2-kinase part of PFKFB-3 as well as PFKFB-4 cDNA and cloned in pcDNA3.1 vector. Pancreatic Panc1 and PSN-1 cancer cells were stable transfected with dnPFKFB-3 and dnPFKFB-4 constructs and studied the expression of endogenous PFKFB-3, PFKFB-4, and VEGF-A mRNAs in these cells as well as its proliferation rate. It was shown that both dnPFKFB-3 and dnPFKFB-4 suppress the expression of endogenous PFKFB-3, PFKFB-4, and VEGF-A mRNAs as well as cell proliferation in pancreatic cancer cells \[95\]. Results of this investigation agree with the role of PFKFB3-driven glycolysis in vessel sprouting \[78,80,81\] and demonstrate possibility to apply the dominant-negative strategy for suppression of tumor cells glycolysis and proliferation through reduction of the expression of PFKFB-3 and PFKFB-4 enzymes.

Figure 11  Representative Western blot analysis of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3, inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4, and hypoxia inducible factor-1α protein levels in breast, lung, colon, and stomach malignant tumors (T) and non-malignant (control) tissues counterparts (N) from same patients. The actin was used to ensure equal loading of the sample\[30,32,33\]. HIF: Hypoxia inducible factor; PFKFB: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.

Figure 12  Representative polyacrylamide gel autoradiograph employed in a typical ribonuclease protection assay of endogenous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 mRNA in pancreatic carcinoma cell line Panc1, stable transfected by pcDNA3.1(+) vector (Panc1 cells) or by dominant/negative 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (Panc1 + dnPFKFB-3) in normoxic (N) condition and after treatment of Panc1 cells with dimethyloxalylglycine, inhibitor of prolyl hydroxylase (I; 1 mmol/L for 6 h). The 18S rRNA antisense probe was used as control of analyzed RNA quantity \[89\]. PFKFB: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.

Figure 13  Quantification of ribonuclease protection assay of endogenous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 mRNA expression in pancreatic carcinoma cell line Panc1, stable transfected by pcDNA3.1(+) vector or dominant/negative 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in normoxic (control) condition (C) and after treatment of Panc1 cells with dimethyloxalylglycine, inhibitor of prolyl hydroxylase (I). \(n = 5; ^bP < 0.01\) vs control \[89\]. dnPFKFB-3: Dominant/negative 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3.
Thus, PFKFB-4 as well as PFKFB-3 participates in the regulation of glycolysis and promotes tumor growth and survival of cancer cells[25,51]. Moreover, targeting PFKFB3 by specific inhibitors is a perspective therapeutic strategy against cancer[91,92]. It was also shown that blocking of PFKFB4 induces reactive oxygen species and cancer cell death and that targeting PFKFB4 may also, therefore, present new therapeutic opportunities[32,52].

CONCLUSION

PFKFB-3 and PFKFB-4 play a significant role in the regulation of glycolysis and cancer growth by inducing cell proliferation and survival. The PFKFB-4 and PFKFB-3 genes have active HIF-responsive elements and its expression is increased in different malignant tumors and strongly induced in various cancer cell lines under hypoxia. The expression of PFKFB-4 and PFKFB-3 genes as well as its hypoxia responsability was also shown for pancreatic (Panc1, PSN-1 and MIA Paca-2) and gastric (MKN45 and NUGC3) cancer cell lines. The highest expression of PFKFB was found in the NUGC3 adenocarcinoma cells and lowest in the Panc1 cells, with the maximum response to hypoxia found in the NUGC3 adenocarcinoma cells and lowest in the Panc1 cells. The overexpression of different PFKFB was also shown in gastric, colon, lung, and breast cancer tissues. It is interesting to note that the protein level of PFKFB-4 in colon and gastric malignant tumors as well as non-malignant tissue counterparts was greater as compared to the variant 3 of PFKFB. Both PFKFB-4 and PFKFB-3 isoenzymes are overexpressed in different malignant tumors and undergo changes in their metabolism that contribute to the proliferation and survival of cancer cells. A better understanding of the impact of PFKFB gene networks regulation on cell cycle control and glycolysis as well as nutrient balance at the molecular, cellular and system levels promises to shed light on the emerging association between PFKFB-3, PFKFB-4, cell proliferation and cancer. These provide rationale for the development of agents that selectively inhibit the PFKFB3 and PFKFB-4 enzymes as antineoplastic agents.

REFERENCES

1. Vaccaro V, Gelibter A, Bria E, Iapicca P, Cappello P, Di Modugno F, Pino MS, Nuzzo C, Cognetti F, Novelli F, Nistico P, Millela M. Molecular and genetic bases of pancreatic cancer. Curr Drug Targets 2012; 13: 731-743 [PMID: 22458519 DOI: 10.2174/13894501012808564077]

2. Thomas SJ, Swanik KA, Swanik C, Huxel KC. Glenuhormonal rotation and scapular position adaptations after a single high school female sports season. J Athl Train 2009; 44: 230-237 [PMID: 19478845 DOI: 10.1097/JAT.0b013e3181b22f14]

3. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-276 [PMID: 11181773]

4. Neelam S, Brooks MM, Cammarata PR. Lenticular cytoprotection. Part I: the role of hypoxia inducible factors-1α and -2α and vascular endothelial growth factor in lens epithelial cell survival in hypoxia. Mol Vis 2013; 19: 1-15 [PMID: 2333846]

5. Chiche J, Rouleau M, Gounon P, Brahimi-Horn MC, Pouysségur J, Mazure NM. Hypoxia enlarged mitochondria protect cancer cells from apoptotic stimuli. J Cell Physiol 2010; 222: 648-657 [PMID: 19957303 DOI: 10.1002/jcp.21984]

6. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med (Berl) 2007; 85: 1301-1307 [PMID: 18026916 DOI: 10.1007/s00109-007-0281-3]

7. Chen C, Cai S, Wang G, Cao X, Yang X, Luo X, Feng Y, Hu J. c-Myc enhances colon cancer cell-mediated angiogenesis through the regulation of HIF-1α. Biochem Biophys Res Commun 2013; 430: 505-511 [PMID: 23237807 DOI: 10.1016/j.bbrc.2012.12.006]

8. Kim EJ, Simeone DM. Advances in pancreatic cancer. Curr Opin Gastroenterol 2011; 27: 460-466 [PMID: 21778878 DOI: 10.1097/MOG.0b013e32835eb317]

9. Ratcliffe PJ, O’Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998; 201: 1153-1162 [PMID: 9510527]

10. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer, Intern Med 2002; 41: 79-83 [PMID: 11868612]

11. Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A, Bucana CD, Semenza GL, Ellis LM. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004; 96: 946-956 [PMID: 15199114 DOI: 10.1093/jnci/djh168]

12. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002; 277: 23111-23115 [PMID: 11945784 DOI: 10.1074/jbc.M202487200]

13. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ.
Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2008; 27: 2977-3005 [PMID: 17759411]

He Y, Kim H, Ryu T, Kang Y, Kim JA, Kim BH, Lee JH, Kang K, Lu Q, Kim K. 6-Catinen overexpression promotes angiogenic potential of CWR22Rv-1 prostate cancer cells via HIF-1α and VEGF. FEBS Lett 2013; 587: 193-199 [PMID: 23220888 DOI: 10.1016/j.febslet.2012.11.024]

Höpf G, Ogunshola O, Gassmann M. HIFs and tumours-causes and consequences. J Physiol Regul Integr Physiol 2004; 286: R606-R625 [PMID: 15009341 DOI: 10.1152/jphysiol.00558.2003]

Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg’s effect. J Bioenerg Biomembr 2007; 39: 223-229 [PMID: 17661613 DOI: 10.1016/s1086-0790-3]

Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in cancer. Exp Mol Pathol 2009; 86: 174-179 [PMID: 19454274 DOI: 10.1016/j.yexmp.2009.01.003]

Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sahna N, Cairns R, Hawkins C, Guha A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011; 210: 313-326 [PMID: 21242296 DOI: 10.1084/jem.20101470]

Okar DA, Manzano A, Navarro-Sabaté A, Riera L, Bartrons R, Lange AJ. PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem Sci 2001; 26: 30-35 [PMID: 11165514]

Rider MH, Bertrand L, Vertommen D, Michals PA, Rousseau GG, Hue L. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. Biochem J 2004; 381: 561-579 [PMID: 15170386 DOI: 10.1042/BJ20040752]

Sakata J, Abe Y, Uyeda K. Molecular cloning of the DNA expression and characterization of rat testes 6-phosphofructo-2-kinase: fructose-2,6-bisphosphatase gene. J Biol Chem 1991; 266: 15764-15770 [PMID: 1651918]

Manzano A, Rosa JL, Ventura F, Pérez JX, Nadal M, Estivill X, Ambrosio S, Gil J, Bartrons R. Molecular cloning, expression, and chromosomal localization of a ubiquitously expressed human 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase gene (PFKFB3). Cytogeten Cell Genet 1998; 83: 214-217 [PMID: 10072580 DOI: 10.1159/000015181]

Sakakibara R, Okudaira T, Fujiwara K, Kato M, Hirata T, Yamanaka S, Naito M, Fukasawa M. Tissue distribution of placenta-type 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Biochem Biophys Res Commun 1999; 257: 177-181 [PMID: 10092529]

Minchenko O, Opentanova I, Caro J. Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB1-4) expression in vivo. FEBS Lett 2003; 535: 264-270 [PMID: 14629377 DOI: 10.1016/s0014-5793(03)01179-7]

Minchenko O, Opentanova I, Minchenko D, Ogura T, Esumi H. Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 gene via hypoxia-inducible factor-1alpha activation. FEBS Lett 2004; 574: 14-20 [PMID: 15474002 DOI: 10.1016/j.febslet.2004.08.053]

Chesney J. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis. Curr Opin Clin Nutr Metab Care 2006; 9: 535-539 [PMID: 16912547]

Minchenko A, Leschinskys I, Opentanova I, Sang N, Srinivasas A, Armstead V, Caro J. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 2002; 277: 6183-6187 [PMID: 11744734]

Chesney J, Mitchell R, Benigni F, Bacher M, Spiegel L, Al-Abed Y, Han JH, Metz C, Bucala R. An inducible gene product for 6-phosphofructo-2-kinase with an AR-rich instabil-
Minchenko OH et al. PFKFB3 expression in pancreatic cancer

in response to stress stimuli. Biochem J 2013; 452: 531-543
[PMID: 23548149 DOI: 10.1042/Bj2011886]

42 Almeida A, Boloños JP, Moncada S. E3 ubiquitin ligase APC/C-Cdc20 accounts for the Warburg effect by linking glycolysis to cell proliferation. Proc Natl Acad Sci USA 2010; 107: 738-741
[PMID: 2008744 DOI: 10.1073/pnas.0913688107]

43 Cordero-Espinoza I, Hagen T. Increased concentrations of fructose 2,6-bisphosphate contribute to the Warburg effect in phosphatase and tensin homolog (PTEN)-deficient cells. J Biol Chem 2013; 288: 36620-36628 [PMID: 24166967 DOI: 10.1074/jbc.M111.310289]

44 Tudzarova S, Colombo SL, Stoeber K, Carcamo S, Williams GH, Moncada S. Two ubiquitin ligases, APC/C-Cdc20 and SKP1-CUL1-F (SCF)-beta-TRCP, sequentially regulate glycolysis during the cell cycle. Proc Natl Acad Sci USA 2011; 108: 5278-5283 [PMID: 21402913 DOI: 10.1073/pnas.1102247108]

45 Moon JS, Jin WJ, Kwak JH, Kim HJ, Yun MJ, Kim JW, Park SW, Kim KS. Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J 2011; 435: 225-233 [PMID: 20958264 DOI: 10.1042/Bj20111014]

46 Ruiz-Garcia A, Monsalve E, Novellasdemunt L, Navarro-Sabaté A, Manzano A, Rivero S, Castrillo A, Casado M, Laborda J, Bartrons R, Díaz-Guerra MJ. Cooperation of adenosine deaminase with macrophage Toll-4 receptor agonists leads to increased glycolytic flux through the enhanced expression of PFKFB3 gene. J Biol Chem 2011; 286: 19247-19258 [PMID: 21464136 DOI: 10.1074/jbc.M110.192098]

47 Kumar P, Sharoyko VV, Spégel P, Gullberg U, Mulder H, Olsson I, Ajore J. The transcriptional co-repressor myeloid differentiation pathway 10.1158/2159-8290.CD-11-0234

49 Zamboni N, Schulze A. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 and -4 as an important regulator of prostate cancer cell survival. Cancer Discov 2012; 2: 304-307 [PMID: 22576206 DOI: 10.1158/2159-8290.CD-12-0489]

53 Dang CV. Cancer cell metabolism: there is no ROS for the weary. Cancer Discov 2012; 2: 181-189 [PMID: 22549953 DOI: 10.1101/gad.189065.112]

54 Minchenko OH, Goura T, Opentanova IL, Minchenko DO, Esmi H. Splice isoforms of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4: expression and hypoxic regulation. Mol Cell Biochem 2008; 282: 227-234 [PMID: 16311927]

57 Mykhalchenko VG, Mykhalchenko DO, Tsichikara H, Komnen M, Komisarenko SV, Bikuflavi A, Esmi H, Minchenko OH. Expression of mouse 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 mRNA alternative splice variants in hypoxia. Ukr Biokhim Zh 2008; 80: 19-25 [PMID: 18710022]

60 Mykhalchenko VG, Mykhalchenko DO, Tsichikara H, Minchenko OH. 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase mRNA expression in streptozotocin-diabetic rats. Biopolymers Cell 2008; 24: 260-266 [DOI: 10.7124/bc.0007A9]

63 Ros S, Santos CR, Moco S, Baenke F, Kelly G, Howell M, Zamboni N, Schulze A. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov 2012; 2: 328-343 [PMID: 22576210 DOI: 10.1158/2159-8290.CD-11-0324]

64 Jeon YK, Yoo DR, Jang YH, Jang SY, Nam MJ. Sulforaphane induces apoptosis in human hepatic cancer cells through inhibition of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase4, mediated by hypoxia inducible factor-1-dependent pathway. Biochim Biophys Acta 2011; 1814: 1340-1348 [PMID: 21648852 DOI: 10.1016/j.bbadap.2011.05.015]

67 Goits V, Bageritz J, Puccio L, Nakata S, Zapatka M, Barbus S, Toedt G, Campos B, Korshunov A, Momma S, Van Schaftingen E, Reifenberger G, Herold-Mende C, Lichter P, Radlwimmer B. RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene 2012; 31: 3235-3243 [PMID: 22056679 DOI: 10.1038/onc.2012.110]

70 Minchenko OH, Spégel P, Gullberg U, Mulder H, Jia X, Duan Y, Xiao H, Sundqvist KG, Permert J, Mykhalchenko VG, Tsuchihara K, Kanehara S, Yavorovsky O, Zapatka M, Barlow J, Ryan HE, Lu H, Wouters BG, Knapp M, Jørgensen J, Boverns P, Kubista J, Lin Y, Polonovski MG, Frezza C, Wachter A, Falcón G, Overbergh L, Berdel WE, Wang F. Excess glucose induces hypoxia-inducible factor-1 in pancreatic cancer cells and stimulates glucose metabolism and cell migration. Cancer Biol Ther 2013; 14: 428-435 [PMID: 23377827 DOI: 10.1042/cbt.213786]

73 Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K, Johnson RS. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 2001; 21: 3436-3444 [PMID: 11313469]

76 Gleadle JM, Ratcliffe PJ. Hypoxia and the regulation of gene expression. Mol Med Today 1998; 4: 122-129 [PMID: 9575495]

78 Minchenko A, Caro J. Regulation of endothelin-1 gene expression in human microvascular endothelial cells by hypoxia and cobalt: role of hypoxia responsive element. Mol Cell Biochem 2000; 208: 53-62 [PMID: 10939628]

81 Bobarykina AIu, Minchenko OH, Vaskovsky O, Vaskovsky Y, Tsichikara H, Komnen M, Komisarenko SV, Esmi H, Minchenko OH. Hypoxia inducible factor (HIF)-1alpha, HIF-2alpha and VHL mRNA expression in different cell lines during hypoxia. Ukr Biokhim Zh 2006; 78: 62-72 [PMID: 17100286]

84 Uchida T, Rossignol F, Matthias MA, Mounier R, Coutette S, Cottes E, Clerici C. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural anti-tumour HIF-2alpha. J Biol Chem 2004; 279: 14871-14878 [PMID: 14744852 DOI: 10.1074/jbc.M400461200]

87 Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transcriptional domain by a hypoxic switch. Science 2002; 295: 858-861 [PMID: 11825634]

90 Mole DR, Schlemminger I, McNeill LA, Hewitson KS, Pugh CW, Ratcliffe PJ, Schofield CJ. 2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase. Bioorg Med Chem Lett 2003; 13: 2677-2680 [PMID: 12873492]

93 Minchenko DO, Bobarykina AIu, Senchenko TY, Hube oyana OV, Tsichikara H, Chiaia A, Momen M, Esmi H, Minchenko OH. Expression of the VEGF, GLUT and HIF-1alpha, HIF-2alpha and GLUT-1 mRNA expression in different cell lines during hypoxia. Ukr Biokhim Zh 2006; 78: 62-72 [PMID: 17100286]

96 Ji D, Lu ZT, Li YQ, Liang ZY, Zhang PF, Li C, Zhang JL, Zheng X, Yao YM. MACC1 expression correlates with
PKFFB2 and survival in hepatocellular carcinoma. Asian Pac J Cancer Prev 2014; 15: 999-1003 [PMID: 24568531]

71 Novellademet L, Tato I, Navarro-Sabate A, Ruiz-Meana M, Méndez-Lucas A, Perales JC, Garcia-Dorado D, Ventura F, Bartrons R, Rosa J. Akt-dependent activation of the heart 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PKFFB2) isoenzyme by amino acids. J Biol Chem 2013; 288: 10640-10651 [PMID: 23457334 DOI: 10.1074/jbc.M113.455998]

72 Moenner M, Pluquet O, Boucheareiil M, Chevet E. Integrated endoplasmic reticulum stress responses in cancer. Cancer Res 2007; 67: 1063-10634 [PMID: 18006802 DOI: 10.1158/0008-5472.CAN-07-1705]

73 Auf G, Jabouille A, Guerit S, Pineau R, Delugan M, Boucheareiil M, Magnin N, Favereau A, Maire M, Gaiser T, von Deimling A, Czabanka M, Vajccky P, Chevet E, Bikfalvi A, Moenner M. Inositol-requiring enzyme alpha1 is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad Sci USA 2010; 107: 15553-15558 [PMID: 20702765 DOI: 10.1073/pnas.0914072107]

74 Auf G, Jabouille A, Delugan M, Guerit S, Pineau R, North S, Platonova N, Maire M, Favereau A, Vajccky P, Seno M, Bikfalvi A, Minchenko D, Minchenko O, Moenner M. High bFGF expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGFR receptor. BMC Cancer 2013; 13: 597 [PMID: 24330607 DOI: 10.1186/1471-2407-13-597]

75 Wang S, Kaufman JR. The impact of the unfolded protein response on human disease. J Cell Biol 2012; 197: 857-867 [PMID: 22739980 DOI: 10.1083/jcb.201111043]

76 Koumenis C. ER stress, hypoxia tolerance and tumor progression. Curr Mol Med 2006; 6: 55-69 [PMID: 16472113 DOI: 10.2174/156652406775576460]

77 Minchenko DO, Marunchyk RY, Komenko EV, Bakalets TV, Minchenko OH. Expression of hexokinase and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase genes in ERN1 knockdown glioma U87 cells: effect of hypoxia and glutamine or glucose deprivation. Studia Biologica 2011; 5: 5-18

78 De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantoelmo AR, Quaegebeur A, Ghesquière B, Cauwenberghs S, Kuchnio A, Welti J, De Bock K, Carmeliet P. Control of vessel sprouting by genetic and metabolic determinants. Trends Endocrinol Metab 2013; 24: 589-596 [PMID: 24075830 DOI: 10.1016/j.tem.2013.08.006]

79 Mace TA, Collins AL, Wojciek SE, Croce CM, Lesinski GB, Bloomston M. Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. J Surg Res 2013; 184: 855-860 [PMID: 23726431 DOI: 10.1016/j.jss.2013.04.061]

80 Kitamoto S, Yokoyama S, Higashi M, Yamada N, Takao S, Yonezawa S. MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors. Oncogene 2013; 32: 4614-4621 [PMID: 23108411 DOI: 10.1038/onc.2012.478]

81 Uh MK, Kandel J, Kitaevsky J. Evaluating tumor angiogenesis. Methods Mol Biol 2013; 980: 341-351 [PMID: 23359165 DOI: 10.1007/978-1-62703-287-2_20]

82 Tung KH, Lin CW, Kuo CC, Li LT, Kuo YH, Lin CW, Wu HC. CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling. Cancer Lett 2013; 328: 38-67 [PMID: 23228632 DOI: 10.1016/j.canlet.2012.12.001]

83 Kappler M, Taubert H, Schubert J, Vordermark D, Eckert AW. The real face of HIF1α in the tumor process. Cell Cycle 2012; 11: 3932-3936 [PMID: 22967151 DOI: 10.4161/cc.21854]

84 Bolanos JP. Adapting glycolysis to cancer cell proliferation: the MAKP pathway focuses on PFKFB3. Biochem J 2013; 452: e7-e9 [PMID: 23725459 DOI: 10.1042/BJ20130560]

85 Sahraei M, Roy LD, Curry JM, Teresa TL, Nath S, Besmer D, Kidyoor A, Dalia R, Gendler SJ, Mukherjee P. MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene 2012; 31: 4935-4945 [PMID: 22266848 DOI: 10.1038/onc.2011.651]

86 Huang X, Ding L, Bennish WT, Kong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35: 856-867 [PMID: 19782034 DOI: 10.1016/j.molcel.2009.09.006]

87 Shi CY, Fan Y, Liu B, Lou WH. HIF1α contributes to hypoxia-induced pancreatic cancer cells invasion via promoting QSOX1 expression. Cell Physiol Biochem 2013; 32: 561-568 [PMID: 24008827 DOI: 10.1159/000354460]

88 Clem BF, O’Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA, Klarer AC, Redman R, Miller DM, Trent JO, Telang S, Chesney J. Targeting 6-phosphofructo-2-kinase (PKFFB3) as a therapeutic strategy against cancer. Mol Cancer Ther 2013; 12: 1461-1470 [PMID: 23674815 DOI: 10.1158/1535-7163.MCT-13-0097]

89 Mac N, Kim JD, Noor D, Sehgal I, Lee YH. Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. PLoS One 2011; 6: e24179 [PMID: 21957443 DOI: 10.1371/journal.pone.0024179]

90 Klarer AC, O’Neal J, Imbert-Fernandez Y, Clem A, Ellis SR, Clark J, Clem B, Chesney J, Telang S. Inhibition of 6-phosphofructo-2-kinase (PKFFB3) induces autophagy as a survival mechanism. Cancer Metab 2014; 2: 2 [PMID: 24451478 DOI: 10.1186/2049-3002-2-2]

91 Yang Z, Gororny JJ, Weyand CM. The glycolytic enzyme PFKFB3/fructosephosphokinase regulates autophagy. Autophagy 2014; 10: 382-383 [PMID: 24351650]

92 Minchenko DO, Bobarykina AY, Ratushna OO, Marunych RY, Tsuchihara K, Moenner M, Caro J, Esumi H, Minchenko OH. Dominant-negative constructs of human 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-2 and -4: effect on the expression of endogenous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase mRNA. Biotechnology 2008; 1: 49-56

P- Reviewer: Ma DX, Paydas S S- Editor: Qi Y L- Editor: A E- Editor: Ma S
